What is the BCI test?
What is the BCI test?
Breast Cancer Index (or BCI) is a new test to help determine if you are likely to benefit from an additional five years of anti-estrogen medication. BCI can also provide additional clarity around the risk of cancer returning between 5-10 years after diagnosis. BCI requires no additional procedure for you.
What is a cancer ID test?
What is the CancerTYPE ID® test? CancerTYPE ID is a standardized, objective molecular test based on the differential expression of 92 genes that classifies tumors by matching the gene expression pattern of a patients tumor tissue to a database of known tumor types and histological subtypes.
Who owns Biotheranostics?
Hologic
BioTheranostics, Inc./Parent organizations
Hologic, Inc. – Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 Million.
What is BCI in breast cancer?
Breast Cancer Index (BCI) is a validated bio-marker test that incorporates 2 distinct genomic assays and is prognostic/predictive. The objective of this study is to assess patient characteristics, pathologic features and patient preferences with regards to extending endocrine therapy after reviewing the BCI results.
How accurate is Oncotype test?
A large population-based observational study based on the SEER registry of more than 40,000 node-negative and 4,500 node-positive patients who received the Oncotype DX test in clinical settings showed Breast Cancer Specific Mortality (BCSM) at five years was less than half a percent in node negative disease and one …
What do you understand by Theranostics?
Theranostics is a combination of the terms therapeutics and diagnostics. Theranostics is the term used to describe the combination of using one radioactive drug to identify (diagnose) and a second radioactive drug to deliver therapy to treat the main tumor and any metastatic tumors.
What is Prosigna test?
The Prosigna Breast Cancer Prognostic Gene Signature Assay (formerly called the PAM50 test), made by Veracyte, is a genomic test that analyzes the activity of certain genes in early-stage, hormone-receptor-positive breast cancer.
